The Texas Institute for Genomic Medicine (TIGM) has entered into an agreement with the Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE) in Spain to supply genetically altered mice over the next three years for use in collaborative research focused on understanding liver function and finding a cure for liver diseases.
The CIC bioGUNE is a nonprofit research and biotechnology business development hub created in Spain’s Basque Country in 2005 to bring together the resources of private industry and government to accelerate the search to identify, prevent and cure sources of human disease.
The research consortium focuses in four primary areas of investigation, including functional genomics, proteomics, stem cells and cellular biology and metabolomics.
Under the terms of the agreement, TIGM will create custom-designed breeding pairs of knockout mice that have specific genes altered especially for the research CIC bioGUNE scientists are conducting in liver disease and hepatocellular carcinoma over the next three years.
“As a leading provider of genetically engineered knockout mice, TIGM provides an essential resource to scientists all over the world. Our agreement with the CIC bioGUNE researchers allows them to accelerate breakthroughs in our understanding of the interaction between lifestyle choices and risk for chronic illness, such as non-alcoholic liver disease,” said Dr. Richard H. Finnell, TIGM president and executive director.
Prof. José M Mato, general director of CIC bioGUNE, noted, “Genetically altered mice are very helpful tools to understand the biology and pathobiology of a gene. Our agreement with TIGM will provide us access to the largest existing knockout mice library.”